{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:44:20Z","timestamp":1779889460968,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/00423, PI19\/0069, PI20\/00436"],"award-info":[{"award-number":["PI16\/00423, PI19\/0069, PI20\/00436"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00277-021-04653-2","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T08:02:51Z","timestamp":1630396971000},"page":"2997-3005","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunoparesis defined by heavy\/light chain pair suppression in smoldering multiple myeloma shows initial isotype specificity and involves other isotypes in advanced disease"],"prefix":"10.1007","volume":"100","author":[{"given":"Ignacio","family":"Isola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Moga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari-Pau","family":"Mena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Tovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aina","family":"Oliver-Cald\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Carmen","family":"Salgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fara","family":"Bras\u00f3-Maristany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Yag\u00fce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Teresa","family":"Cibeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleix","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rosi\u00f1ol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Blad\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Fern\u00e1ndez de Larrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"issue":"1","key":"4653_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/PPO.0000000000000350","volume":"25","author":"P Kapoor","year":"2019","unstructured":"Kapoor P, Rajkumar SV (2019) Smoldering multiple myeloma: to treat or not to treat. Cancer J 25(1):65\u201371. https:\/\/doi.org\/10.1097\/PPO.0000000000000350","journal-title":"Cancer J"},{"issue":"2","key":"4653_CR2","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood-2007-08-108357","volume":"111","author":"A Dispenzieri","year":"2008","unstructured":"Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, Clark RJ, Melton LJ 3rd, Gertz MA, Kumar SK, Fonseca R, Jelinek DF, Rajkumar SV (2008) Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111(2):785\u2013789. https:\/\/doi.org\/10.1182\/blood-2007-08-108357","journal-title":"Blood"},{"issue":"7","key":"4653_CR3","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","volume":"110","author":"E P\u00e9rez-Persona","year":"2007","unstructured":"P\u00e9rez-Persona E, Vidriales MB, Mateo G, Garc\u00eda-Sanz R, Mateos MV, de Coca AG, Galende J, Mart\u00edn-Nu\u00f1ez G, Alonso JM, de Las HN, Hern\u00e1ndez JM, Mart\u00edn A, L\u00f3pez-Berges C, Orfao A, San Miguel JF (2007) New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110(7):2586\u20132592. https:\/\/doi.org\/10.1182\/blood-2007-05-088443","journal-title":"Blood"},{"issue":"10","key":"4653_CR4","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","volume":"10","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Kumar S, Dimopoulos MA, Gonz\u00e1lez-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J (2020) International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J 10(10):102. https:\/\/doi.org\/10.1038\/s41408-020-00366-3","journal-title":"Blood Cancer J"},{"issue":"2","key":"4653_CR5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/leu.2015.291","volume":"30","author":"E Zamagni","year":"2016","unstructured":"Zamagni E, Nanni C, Gay F, Pezzi A, Patriarca F, Bell\u00f2 M, Rambaldi I, Tacchetti P, Hillengass J, Gamberi B, Pantani L, Magarotto V, Versari A, Offidani M, Zannetti B, Carobolante F, Balma M, Musto P, Rensi M, Mancuso K, Dimitrakopoulou-Strauss A, Chauvi\u00e8 S, Rocchi S, Fard N, Marzocchi G, Storto G, Ghedini P, Palumbo A, Fanti S, Cavo M (2016) 18F-FDG PET\/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease. Leukemia 30(2):417\u2013422. https:\/\/doi.org\/10.1038\/leu.2015.291","journal-title":"Leukemia"},{"issue":"25","key":"4653_CR6","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle RA, Remstein ED, Therneau TM, Dispenzieri A, Kurtin PJ, Hodnefield JM, Larson DR, Plevak MF, Jelinek DF, Fonseca R, Melton LJ 3rd, Rajkumar SV (2007) Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med 356(25):2582\u20132590. https:\/\/doi.org\/10.1056\/NEJMoa070389","journal-title":"N Engl J Med"},{"issue":"8","key":"4653_CR7","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1038\/leu.2013.86","volume":"27","author":"SV Rajkumar","year":"2013","unstructured":"Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D, Ketterling RP, Lust JA, Kyle RA, Kumar SK (2013) Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 27(8):1738\u20131744. https:\/\/doi.org\/10.1038\/leu.2013.86","journal-title":"Leukemia"},{"issue":"6","key":"4653_CR8","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1038\/s41375-018-0013-4","volume":"32","author":"C Fern\u00e1ndez de Larrea","year":"2018","unstructured":"Fern\u00e1ndez de Larrea C, Isola I, Pereira A, Cibeira MT, Magnano L, Tovar N, Rodr\u00edguez-Lobato LG, Calvo X, Ar\u00f3stegui JI, D\u00edaz T, Lozano E, Rozman M, Yag\u00fce J, Blad\u00e9 J, Rosi\u00f1ol L (2018) Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression. Leukemia 32(6):1427\u20131434. https:\/\/doi.org\/10.1038\/s41375-018-0013-4","journal-title":"Leukemia"},{"issue":"7","key":"4653_CR9","doi-asserted-by":"publisher","first-page":"e454","DOI":"10.1038\/bcj.2016.65","volume":"6","author":"P Ravi","year":"2016","unstructured":"Ravi P, Kumar S, Larsen JT, Gonsalves W, Buadi F, Lacy MQ, Go R, Dispenzieri A, Kapoor P, Lust JA, Dingli D, Lin Y, Russell SJ, Leung N, Gertz MA, Kyle RA, Bergsagel PL, Rajkumar SV (2016) Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma. Blood Cancer J 6(7):e454. https:\/\/doi.org\/10.1038\/bcj.2016.65","journal-title":"Blood Cancer J"},{"issue":"1","key":"4653_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1182\/blood-2013-07-515239","volume":"123","author":"MV Dhodapkar","year":"2014","unstructured":"Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B, Petty N, Shaughnessy JD Jr, Hoering A, Crowley J, Orlowski RZ, Barlogie B (2014) Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 123(1):78\u201385. https:\/\/doi.org\/10.1182\/blood-2013-07-515239","journal-title":"Blood"},{"issue":"10","key":"4653_CR11","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1038\/leu.2016.123","volume":"30","author":"V Gonz\u00e1lez-Calle","year":"2016","unstructured":"Gonz\u00e1lez-Calle V, D\u00e1vila J, Escalante F, de Coca AG, Aguilera C, L\u00f3pez R, B\u00e1rez A, Alonso JM, Hern\u00e1ndez R, Hern\u00e1ndez JM, de la Fuente P, Puig N, Ocio EM, Guti\u00e9rrez NC, Garc\u00eda-Sanz R, Mateos MV (2016) Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma. Leukemia 30(10):2026\u20132031. https:\/\/doi.org\/10.1038\/leu.2016.123","journal-title":"Leukemia"},{"issue":"1","key":"4653_CR12","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/leu.2012.189","volume":"27","author":"JA Katzmann","year":"2013","unstructured":"Katzmann JA, Clark R, Kyle RA, Larson DR, Therneau TM, Melton LJ 3rd, Benson JT, Colby CL, Dispenzieri A, Landgren O, Kumar S, Bradwell AR, Cerhan JR, Rajkumar SV (2013) Suppression of uninvolved immunoglobulins defined by heavy\/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 27(1):208\u2013212. https:\/\/doi.org\/10.1038\/leu.2012.189","journal-title":"Leukemia"},{"issue":"3","key":"4653_CR13","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/ajh.24268","volume":"91","author":"H Ludwig","year":"2016","unstructured":"Ludwig H, Milosavljevic D, Berlanga O, Zojer N, H\u00fcbl W, Fritz V, Harding S (2016) Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed\/refractory patients with myeloma. Am J Hematol 91(3):295\u2013301. https:\/\/doi.org\/10.1002\/ajh.24268","journal-title":"Am J Hematol"},{"issue":"6","key":"4653_CR14","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/bjh.16488","volume":"189","author":"R Chakraborty","year":"2020","unstructured":"Chakraborty R, Rybicki L, Nakashima MO, Dean RM, Faiman BM, Samaras CJ, Rosko N, Dysert H, Valent J, Anwer F (2020) Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma. Br J Haematol 189(6):1074\u20131082. https:\/\/doi.org\/10.1111\/bjh.16488","journal-title":"Br J Haematol"},{"key":"4653_CR15","doi-asserted-by":"crossref","unstructured":"Costello R, Espana K, Korde N, Kwok M, Zingone A, Yancey MA, Mulquin M, Maric I, Calvo K, Tembhare PR, Yuan C, Stetler-Stevenson M, Landgren O (2011) Hevylite\u2122 assays detect a hidden immunoparesis associated with adverse biology in myeloma precursor disease: a prospective clinical study.\u00a0Blood\u00a0118(21):5065","DOI":"10.1182\/blood.V118.21.5065.5065"},{"issue":"6","key":"4653_CR16","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/j.clml.2016.02.034","volume":"16","author":"L Magnano","year":"2016","unstructured":"Magnano L, Fern\u00e1ndez de Larrea C, Elena M, Cibeira MT, Tovar N, Ar\u00f3stegui JI, Pedrosa F, Rosi\u00f1ol L, Filella X, Yag\u00fce J, Blad\u00e9 J (2016) Prognostic impact of serum heavy\/light chain pairs in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma: long-term results from a single institution. Clin Lymphoma Myeloma Leuk 16(6):e71-7. https:\/\/doi.org\/10.1016\/j.clml.2016.02.034","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4653_CR17","doi-asserted-by":"crossref","unstructured":"International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121(5):749-57.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"issue":"10","key":"4653_CR18","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1093\/annonc\/mdy335","volume":"29","author":"L Par\u00e9","year":"2018","unstructured":"Par\u00e9 L, Pascual T, Segu\u00ed E, Teixid\u00f3 C, Gonzalez-Cao M, Galv\u00e1n P, Rodr\u00edguez A, Gonz\u00e1lez B, Cuatrecasas M, Pineda E, Torn\u00e9 A, Crespo G, Martin-Algarra S, P\u00e9rez-Ruiz E, Reig \u00d2, Viladot M, Font C, Adamo B, Vidal M, Gaba L, Mu\u00f1oz M, Victoria I, Ruiz G, Vi\u00f1olas N, Mellado B, Maurel J, Garcia-Corbacho J, Molina-Vila M\u00c1, Juan M, Llovet JM, Reguart N, Arance A, Prat A (2018) Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types. Ann Oncol 29(10):2121\u20132128. https:\/\/doi.org\/10.1093\/annonc\/mdy335","journal-title":"Ann Oncol"},{"issue":"3","key":"4653_CR19","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ccell.2020.06.002","volume":"38","author":"O Dufva","year":"2020","unstructured":"Dufva O, P\u00f6l\u00f6nen P, Br\u00fcck O, Ker\u00e4nen MAI, Klievink J, Mehtonen J, Huuhtanen J, Kumar A, Malani D, Siitonen S, Kankainen M, Ghimire B, Lahtela J, Mattila P, V\u00e4h\u00e4-Koskela M, Wennerberg K, Granberg K, Leivonen SK, Meriranta L, Heckman C, Lepp\u00e4 S, Nykter M, Lohi O, Hein\u00e4niemi M, Mustjoki S (2020) Immunogenomic landscape of hematological malignancies. Cancer Cell 38(3):380-399.e13. https:\/\/doi.org\/10.1016\/j.ccell.2020.06.002","journal-title":"Cancer Cell"},{"issue":"1","key":"4653_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1158\/2326-6066.CIR-15-0055","volume":"4","author":"DJ Chung","year":"2016","unstructured":"Chung DJ, Pronschinske KB, Shyer JA, Sharma S, Leung S, Curran SA, Lesokhin AM, Devlin SM, Giralt SA, Young JW (2016) T-cell exhaustion in multiple myeloma relapse after autotransplant: optimal timing of immunotherapy. Cancer Immunol Res 4(1):61\u201371. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0055","journal-title":"Cancer Immunol Res"},{"issue":"17","key":"4653_CR21","doi-asserted-by":"publisher","first-page":"4688","DOI":"10.1158\/1078-0432.CCR-19-3673","volume":"26","author":"E Lozano","year":"2020","unstructured":"Lozano E, Mena MP, D\u00edaz T, Martin-Antonio B, Le\u00f3n S, Rodr\u00edguez-Lobato LG, Oliver-Cald\u00e9s A, Cibeira MT, Blad\u00e9 J, Prat A, Rosi\u00f1ol L, Fern\u00e1ndez de Larrea C (2020) Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma. Clin Cancer Res. 26(17):4688\u20134698. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3673","journal-title":"Clin Cancer Res."},{"issue":"21","key":"4653_CR22","doi-asserted-by":"publisher","first-page":"5183","DOI":"10.1158\/1078-0432.CCR-16-0933","volume":"22","author":"SJ Blake","year":"2016","unstructured":"Blake SJ, Dougall WC, Miles JJ, Teng MW, Smyth MJ (2016) Molecular pathways: targeting CD96 and TIGIT for cancer immunotherapy. Clin Cancer Res 22(21):5183\u20135188. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0933","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4653_CR23","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1373\/jalm.2017.024307","volume":"2","author":"Juana J Jim\u00e9nez","year":"2018","unstructured":"Jim\u00e9nez Juana J, Pais Tiago M, Barbosa Nuno, Campos Maria Luisa, D\u00edaz Maria Antonia Pe\u00f1alver, de Larramendi Carmen H (2018) Severe isotype-matched immunosuppression (IMI) as a potential risk factor for progression of MGUS patients. J Appl Lab Med 2(5):700\u2013710","journal-title":"J Appl Lab Med"},{"issue":"5","key":"4653_CR24","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4149\/neo_2015_100","volume":"62","author":"T Pika","year":"2015","unstructured":"Pika T, Lochman P, Sandecka V, Maisnar V, Minarik J, Tichy M, Zapletalova J, Solcova L, Scudla V, Hajek R (2015) Immunoparesis in MGUS - relationship of uninvolved immunoglobulin pair suppression and polyclonal immunoglobuline levels to MGUS risk categories. Neoplasma 62(5):827\u2013832. https:\/\/doi.org\/10.4149\/neo_2015_100","journal-title":"Neoplasma"},{"key":"4653_CR25","doi-asserted-by":"publisher","unstructured":"Paiva B, Vidriales MB, Mateo G, P\u00e9rez JJ, Montalb\u00e1n MA, Sureda A, Montejano L, Guti\u00e9rrez NC, Garc\u00eda de Coca A, de las Heras N, Mateos MV, L\u00f3pez-Berges MC, Garc\u00eda-Boyero R, Galende J, Hern\u00e1ndez J, Palomera L, Carrera D, Mart\u00ednez R, de la Rubia J, Mart\u00edn A, Gonz\u00e1lez Y, Blad\u00e9 J, Lahuerta JJ, Orfao A, San-Miguel JF; GEM (Grupo Espa\u00f1ol de MM)\/PETHEMA (Programa para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas) Cooperative Study Groups (2009) The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients. Blood. 114(20):4369\u201372. https:\/\/doi.org\/10.1182\/blood-2009-05-221689.","DOI":"10.1182\/blood-2009-05-221689"},{"key":"4653_CR26","doi-asserted-by":"publisher","unstructured":"Paiva B, P\u00e9rez-Andr\u00e9s M, V\u00eddriales MB, Almeida J, de las Heras N, Mateos MV, L\u00f3pez-Corral L, Guti\u00e9rrez NC, Blanco J, Oriol A, Hern\u00e1ndez MT, de Arriba F, de Coca AG, Terol MJ, de la Rubia J, Gonz\u00e1lez Y, Mart\u00edn A, Sureda A, Schmidt-Hieber M, Schmitz A, Johnsen HE, Lahuerta JJ, Blad\u00e9 J, San-Miguel JF, Orfao A; GEM (Grupo Espa\u00f1ol de MM)\/PETHEMA (Programa para el Estudio de la Terap\u00e9utica en Hemopat\u00edas Malignas); Myeloma Stem Cell Network (MSCNET) (2011) Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia. 25(4):697\u2013706. https:\/\/doi.org\/10.1038\/leu.2010.320.","DOI":"10.1038\/leu.2010.320"},{"issue":"3","key":"4653_CR27","first-page":"274","volume":"31","author":"L Wang","year":"2001","unstructured":"Wang L, Young DC (2001) Suppression of polyclonal immunoglobulin production by M-proteins shows isotype specificity. Ann Clin Lab Sci 31(3):274\u2013278","journal-title":"Ann Clin Lab Sci"},{"key":"4653_CR28","unstructured":"Hoover RG, Lynch RG (1980) Lymphocyte surface membrane immunoglobulin in myeloma. II. T cells with IgA-Fc receptors are markedly increased in mice with IgA plasmacytomas. J Immunol 125(3):1280\u20138."},{"key":"4653_CR29","unstructured":"Hoover RG, Dieckgraefe BK, Lake J, Kemp JD, Lynch RG (1982) Lymphocyte surface membrane immunoglobulin in myeloma. III. IgA plasmacytomas induce large numbers of circulating, adult-thymectomy-sensitive, theta +, Lyt-1\u20132+ lymphocytes with IgA-Fc receptors. J Immunol 129(6):2329\u201331."},{"key":"4653_CR30","doi-asserted-by":"publisher","unstructured":"Milburn GL, Lynch RG (1982). Immunoregulation of murine myeloma in vitro. II. Suppression of MOPC-315 immunoglobulin secretion and synthesis by idiotype-specific suppressor T cells. J Exp Med 155(3):852\u201362. https:\/\/doi.org\/10.1084\/jem.155.3.852","DOI":"10.1084\/jem.155.3.852"},{"issue":"2","key":"4653_CR31","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3109\/08830188709044754","volume":"2","author":"TJ Waldschmidt","year":"1987","unstructured":"Waldschmidt TJ, Williams KR, Lynch RG (1987) Isotype-specific recognition and regulation by T cells studied with tumor models. Int Rev Immunol 2(2):203\u2013220. https:\/\/doi.org\/10.3109\/08830188709044754","journal-title":"Int Rev Immunol"},{"issue":"8","key":"4653_CR32","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","volume":"32","author":"JLJ Heaney","year":"2018","unstructured":"Heaney JLJ, Campbell JP, Iqbal G, Cairns D, Richter A, Child JA, Gregory W, Jackson G, Kaiser M, Owen R, Davies F, Morgan G, Dunn J, Drayson MT (2018) Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials. Leukemia 32(8):1727\u20131738. https:\/\/doi.org\/10.1038\/s41375-018-0163-4","journal-title":"Leukemia"},{"issue":"6","key":"4653_CR33","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR (2012) Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol 158(6):727\u2013738. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09241","journal-title":"Br J Haematol"},{"issue":"13","key":"4653_CR34","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1158\/1078-0432.CCR-15-2224","volume":"22","author":"E Sanchez","year":"2016","unstructured":"Sanchez E, Gillespie A, Tang G, Ferros M, Harutyunyan NM, Vardanyan S, Gottlieb J, Li M, Wang CS, Chen H, Berenson JR (2016) Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin Cancer Res 22(13):3383\u20133397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2224","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4653_CR35","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","volume":"54","author":"BM Cherry","year":"2013","unstructured":"Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O (2013) Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 54(10):2215\u20132218. https:\/\/doi.org\/10.3109\/10428194.2013.764419","journal-title":"Leuk Lymphoma"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-021-04653-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04653-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T14:04:55Z","timestamp":1636985095000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-021-04653-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["4653"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04653-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"12 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Study protocol was approved by the Institutional Review Board at Hospital Cl\u00ednic of Barcelona.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Sample collection and clinical record review were performed after informed written consent in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Sample collection and clinical record review were performed after informed written consent in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.F.L. has received research grants and consultancy by The Binding Site. All other authors declare no conflict of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}